CHICAGO (Reuters) – The United States prepares a massive screening effort involving more than 100,000 volunteers and a half dozen or two of the most appealing vaccine candidates in an effort to provide a safe and efficient one by the end of 2020, scientists leading the program told Reuters.
FILE PICTURE: Small bottles labeled with a “Vaccine COVID-19” sticker and a medical syringe are seen in this illustration taken April 10,2020 REUTERS/Dado Ruvic/Illustration/File Picture
The job will compress what is generally 10 years of vaccine advancement and screening into a matter of months, testament to the urgency to stop a pandemic that has contaminated more than 5 million individuals, killed over 335,000 and battered economies worldwide.
To get there, leading vaccine makers have actually agreed to share data and provide making use of their medical trial networks to competitors must their own prospect stop working, the scientists stated.
Prospects that demonstrate security in little early studies will be checked in big trials of 20,000 to 30,000 subjects for each vaccine, slated to begin in July.
Between 100,000 and 150,000 individuals might be registered in the studies, said Dr. Larry Corey, a vaccine specialist at Fred Hutchinson Cancer Center in Seattle, who is assisting develop the trials. “If you don’t see a safety issue, you simply keep going,” Dr. Francis Collins, director of the National Institutes of Health (NIH), informed Reuters. The vaccine effort belongs to a public-private collaboration called Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) revealed last month.
The effort suits the research study an